Issues related to reforming and increasing transparency within the 340B Drug Pricing Program.
2025 · 4th Quarter (Oct 1 - Dec 31)
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
Filed by THE MCMANUS GROUP.
Open official filingSource-reported fields
Filing overview
- Type
- 4th Quarter - Report
- Posted
- Jan 20, 2026
- Income
- $60,000.00
- Expenses
- Not reported
- Registrant
- THE MCMANUS GROUP
- Filing UUID
- 9bc7f1fd-8055-43cf-91c4-2596547bb12b
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169- Inflation Reduction Act of 2022. Support for EPIC Act - S. 832, and H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Policies related to the Most Favored Nation Drug Pricing Model S.3345 - PBM Price Transparency and Accountability Act
Literal federal measure citations: S. 832, H.R. 1492, H.R. 4299, S.3345
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.